Latest News

In new era of gene therapy, PCPs are ‘boots on the ground’


 

The whole patient

Primary care physicians will not be expected to be experts in gene therapy or solely in charge of patient safety. They will have support from industry and subspecialists leading the development of these treatments, experts agreed.

But generalists should expect to be drawn into multidisciplinary care teams, be the sounding boards for patients making decisions about gene therapy, help arrange insurance coverage, and be the recipients of late-night phone calls about side effects.

All that, while never losing sight of the child’s holistic health. In children so sick, specialists, subspecialists, and even parents tend to focus only on the rare disease. The team can “get distracted from good normal routine care,” Dr. Nelson said. But these children aren’t exempt from check-ups, vaccine regimens, or the other diseases of childhood.

“In a world where we mitigate that core disease,” he said, “we need a partner in the general pediatrics community” investing in their long-term health.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

New outbreaks of Marburg virus disease: What clinicians need to know
MDedge Pediatrics
Low disease state for childhood lupus approaches validation
MDedge Pediatrics
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
MDedge Pediatrics
FDA approves Yuflyma as ninth adalimumab biosimilar
MDedge Pediatrics
Scientists discover variants, therapy for disabling pansclerotic morphea
MDedge Pediatrics
Systemic JIA and AOSD are the same disease, EULAR says
MDedge Pediatrics
Girls with congenital diaphragmatic hernia have lower survival rates
MDedge Pediatrics
FDA approves ritlecitinib for ages 12 and up for alopecia areata
MDedge Pediatrics
New guidelines for MTX use in pediatric inflammatory skin disease unveiled
MDedge Pediatrics
Camp Discovery: A place for children to be comfortable in their own skin
MDedge Pediatrics